<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02341807</url>
  </required_header>
  <id_info>
    <org_study_id>AAV2-hCHM-101</org_study_id>
    <nct_id>NCT02341807</nct_id>
  </id_info>
  <brief_title>Safety and Dose Escalation Study of AAV2-hCHM in Subjects With CHM (Choroideremia) Gene Mutations</brief_title>
  <official_title>A Phase 1/2 Safety Study in Subjects With CHM (Choroideremia) Gene Mutations Using an Adeno-Associated Virus Serotype 2 Vector to Deliver the Normal Human CHM Gene [AAV2-hCHM] to the Retina</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spark Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Spark Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study evaluates the safety and tolerability of AAV2-hCHM in subjects with&#xD;
      Choroideremia gene mutations. Two dose groups will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to evaluate the safety and tolerability of subretinal administration&#xD;
      of AAV2-hCHM, in an inter-subject group dose escalation in individuals with choroideremia,&#xD;
      based on a comprehensive clinical monitoring plan. The secondary objectives are to define the&#xD;
      dose of AAV2-hCHM required to achieve stable, or improved, visual function/functional vision&#xD;
      and to assess development of immune responses to AAV2 and REP-1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability (assessed by physical exam, vital signs, laboratory changes over time, and adverse events)</measure>
    <time_frame>5 years</time_frame>
    <description>Safety and tolerability of a single dose of AAV2-hCHM will be assessed by physical exam, vital signs, laboratory changes over time, and adverse events.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Choroideremia</condition>
  <condition>CHM (Choroideremia) Gene Mutations</condition>
  <arm_group>
    <arm_group_label>Dose Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, unilateral administration of a single low dose range of AAV2-hCHM.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single, unilateral administration of a single high dose range of AAV2-hCHM.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AAV2-hCHM</intervention_name>
    <description>Comparison of different dosages of AAV2-hCHM</description>
    <arm_group_label>Dose Group 1</arm_group_label>
    <arm_group_label>Dose Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male at least 18 years of age diagnosed with CHM gene mutation&#xD;
&#xD;
          -  Central visual field (VF) &lt; 30° in any of the 24 meridians (using Goldmann perimetry&#xD;
             III4e isopter) in the eye to be injected&#xD;
&#xD;
          -  Any evidence of functioning outer retinal cells within the central 10°&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of ocular inflammatory disease (uveitis)&#xD;
&#xD;
          -  Prior intraocular surgery within six months&#xD;
&#xD;
          -  Participation in a previous gene therapy research trial within one year of enrollment&#xD;
             or participation in any other ocular gene therapy trial&#xD;
&#xD;
          -  Participation in a clinical study with an investigational drug in the past six months&#xD;
&#xD;
          -  Grossly asymmetrical disease, or other eye morbidity, which may render the&#xD;
             contralateral eye ineffective as a control&#xD;
&#xD;
          -  Visual acuity &lt; 20/200 on standard ETDRS testing in the eye to be injected&#xD;
&#xD;
          -  Presence of disease which may preclude the subject from participation in this trial&#xD;
&#xD;
          -  Use of medications known to be neuroprotective or retino-toxic that could potentially&#xD;
             interfere with the disease process and/or cause ocular adverse events; individuals who&#xD;
             discontinue use of these compounds for 6 months may become eligible&#xD;
&#xD;
          -  Identification by the investigator as being unable or unwilling to perform / be&#xD;
             compliant with study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Director</last_name>
    <role>Study Director</role>
    <affiliation>Spark Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 12, 2015</study_first_submitted>
  <study_first_submitted_qc>January 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2015</study_first_posted>
  <last_update_submitted>July 14, 2021</last_update_submitted>
  <last_update_submitted_qc>July 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Choroideremia</keyword>
  <keyword>AAV</keyword>
  <keyword>Gene therapy</keyword>
  <keyword>CHM</keyword>
  <keyword>Adeno-associated virus</keyword>
  <keyword>Adeno-associated viral vector</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Choroideremia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

